gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · MRVIHealthcarePharmaceuticals

Maravai LifeSciences Holdings, Inc. Class A Common Stock (MRVI)

$6.98−9.59%
Close Nov 5, 2026 · split-adjusted
Nov 5, 2026$7.05▲ 145.82% in range
Nov 5, 2025Low $2.83 · High $9.00Nov 5, 2026
What changed · written from our data
As of Nov 5, 2026

Maravai LifeSciences Holdings closed at $6.98 on Nov 5, down 9.59%, 22.4% below its 52-week closing high. Volume of 3.2M shares was 1.36× its 20-day average (above normal).

Split-adjusted performance: -6.1% over one month, +77.2% over six months, +143.2% over one year.

In the quarter ended Jun 30, 2026, revenue was $51.44M, up 8.5% from a year earlier, with a net margin of -24.1%.

Short interest was 13.3M shares at the Oct 15 settlement, down 3.5% from the prior report (10.7% of float, 4.5 days to cover).

Market cap$1.04B149.0M shares
Revenue · quarter$51.4M+8.5% YoY
Diluted EPS$-0.08—
P/E · TTM—P/S 5.0×
Net margin-24.1%Gross 40.1%
Dividend yieldNone
52-week range2.83 – 9.00−22.4% from high
Volume3.2M1.36× 20-day avg
Volatility · 60d88.9%Annualised
Short % of float10.7%4.5 days to cover
Net cash-$106.6MCash $70.1M
Next earnings—Not scheduled
Split-adjusted performance
1W −17.5%1M −6.1%3M +12.0%6M +77.2%YTD +114.8%1Y +143.2%3Y +1.7%5Y −83.4%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum98
Revenue growth55
Net margin55
Value (low P/E)—
Size71

Industry medians: 6-month return −28.4%, revenue growth +5.9%, net margin −38.9%, P/E 15.0×.

Short interest

Details →
Shares short13.3M−3.5% vs prior
Days to cover4.5Settled Oct 15
% of float10.7%
Short vol. 10d41.4%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
MRVIMaravai LifeSciences Holdings$6.98−9.59%+77.2%+8.5%−24.1%—$1.04B
SPTXSeaport Therapeutics$20.39−2.72%————$1.09BCompare
JANXJanux Therapeutics$16.06−11.66%+10.5%—−214.0%—$981.9MCompare
HROWHarrow$26.04−9.43%−33.3%+10.9%−24.4%—$976.2MCompare
VSTMVerastem$9.38−4.77%+65.7%+1775.4%−86.5%—$1.14BCompare
AMPHAmphastar Pharmaceuticals$27.66−1.28%+15.1%+5.4%16.5%15.0$1.18BCompare
MLTXMoonLake Immunotherapeutics$10.80−6.57%−37.2%———$919.2MCompare
AVLNAvalyn Pharma$26.67−2.91%————$1.18BCompare
SVRASavara$4.38−6.01%−15.1%———$899.9MCompare

News about Maravai LifeSciences Holdings

All news →
Maravai LifeSciences Holdings, Inc. (MRVI) Reports Q3 Loss, Beats Revenue EstimatesZacks Investment Research · 1d agoNeutral

Quick answers

What does Maravai LifeSciences Holdings do?
Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications.
What is MRVI's market cap?
$1.04B, based on the Nov 5 close of $6.98.
Does Maravai LifeSciences Holdings pay a dividend?
No regular cash dividend has been paid in the last year.
How much of MRVI is sold short?
13.3M shares, 10.7% of float, as of Oct 15, 2026.
What sector is MRVI in?
Healthcare, in the Pharmaceuticals industry.

About Maravai LifeSciences Holdings

Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.

HQ: San Diego, CA415 employeesListed Nov 20, 2020maravai.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology